This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dumas, C. Articles by Papadopoulou, B. Search for Related Content PubMed PubMed Citation Articles by Dumas, C. Articles by Papadopoulou, B.

Recombinant Leishmania major Secreting Biologically Active Granulocyte-Macrophage Colony-Stimulating Factor Survives Poorly in Macrophages In Vitro and Delays Disease Development in Mice

Carole Dumas, Anthony Muyombwe, Gaétan Roy, Claudine Matte, Marc Ouellette, Martin Olivier,^* and Barbara Papadopoulou^*

Infectious Diseases Research Center, CHUL Research Center, Department of Medical Biology, Faculty of Medicine, Laval University, Quebec, Canada

Received 7 February 2003/ Returned for modification 8 April 2003/ Accepted 6 August 2003

Leishmania is an intracellular pathogen that replicates inside macrophages. Activated macrophages produce a specific subset of cytokines that play an important role in the control of Leishmania infections. As part of our interest in developing suicide parasites that produce abortive infections for the purposes of vaccination, we engineered recombinant Leishmania major strains producing biologically active granulocyte-macrophage colony-stimulating factor (GM-CSF). We showed that GM-CSF is being produced in the phagosomes of infected macrophages and that it can be detected in the culture supernatants of both infected macrophages and extracellular parasites. Our data support the notion that GM-CSF secreted by both developmental forms of recombinant L. major can activate macrophages to produce high levels of proinflammatory cytokines such as interleukin-1ß (IL-1ß), IL-6, and IL-18 and various chemokines including RANTES/CCL5, MIP-1/CCL3, MIP-1ß/CCL4, MIP-2/CXCL2, and MCP-1/CCL2, which enhance parasite killing. Indeed, GM-CSF-expressing parasites survive poorly in macrophages in vitro and produce delayed lesion development in susceptible BALB/c mice in vivo. Selective killing of intracellular Leishmania expressing cytokine genes capable of activating cellular responses may constitute a promising strategy to control and/or prevent parasitic infections.

Editor: J. M. Mansfield

Present address: Department of Microbiology and Immunology, University of Montreal, Montreal, Quebec, Canada.

This article has been cited by other articles:

• Field, A. E., Wagage, S., Conrad, S. M., Mosser, D. M. (2007). Reduced Pathology following Infection with Transgenic Leishmania major Expressing Murine CD40 Ligand. Infect. Immun. 75: 3140-3149 [Abstract] [Full Text]  
• Elshafie, A. I., Ahlin, E., Mathsson, L., ElGhazali, G., Ronnelid, J. (2007). Circulating Immune Complexes (IC) and IC-Induced Levels of GM-CSF Are Increased in Sudanese Patients with Acute Visceral Leishmania donovani Infection Undergoing Sodium Stibogluconate Treatment: Implications for Disease Pathogenesis. J. Immunol. 178: 5383-5389 [Abstract] [Full Text]  
• Vasquez, R. E., Soong, L. (2006). CXCL10/Gamma Interferon-Inducible Protein 10-Mediated Protection against Leishmania amazonensis Infection in Mice. Infect. Immun. 74: 6769-6777 [Abstract] [Full Text]  
• Breton, M., Tremblay, M. J, Ouellette, M., Papadopoulou, B. (2005). Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral Leishmaniasis. Infect. Immun. 73: 6372-6382 [Abstract] [Full Text]